Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 255

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis

Naderpoor, Negar, Shorakae, Soulmaz, de Courten, Barbora, Misso, Marie L., Moran, Lisa J., Teede, Helena J. · 2016 · Human Reproduction Update

Abstract

Joint senior authors. Joint senior authors. Hum. Reprod Update. 2015;21:560–574 The authors would like to apologise for an error in the specific meta-analysis examining the effect of 6 months of lifestyle + metformin treatment vs lifestyle ± placebo treatment in patients with polycystic ovary syndrome (PCOS). This error arose as a result of inaccurate data transfer from a single extraction table of data from Karimzadeh and Javedani (Karimzadeh and Javedani, 2010) and Ladson studies (Ladson et al., 2011a, b) to RevMan analysis software. With limited BMI data at 6 months comparing these two groups, data was obtained from original manuscripts and directly from contacted authors and a new meta-analysis has been performed for change in BMI over 6 months, showing a greater, though not statistically significant reduction in BMI with lifestyle + metformin vs lifestyle ± placebo (95%CI: -0.85, 0.01, p = 0.06) (Figure 3). In the text below we have described the amendments. In the Results section of the abstract (page 561): “Lifestyle and metformin were associated with lower BMI (mean difference (MD) -0.73 kg/m2, 95% confidence intervals (CI) -1.14, -0.32, P = 0.0005) and subcutaneous adipose tissue (MD -92.49cm2, 95% CI -164.14, -20.84, P = 0.01) and increased number of menstrual cycles (MD 1.06, 95% CI 0.30, 1.82, P = 0.006) after 6 months compared with lifestyle ± placebo.” should be corrected to “Lifestyle and metformin was associated with a greater BMI reduction over 6 months which didn't reach statistical significance (mean difference (MD) -0.42 kg/m2, 95% confidence intervals (CI) -0.85,0.01, P = 0.06), lower subcutaneous adipose tissue (MD -92.49cm2, 95% CI -164.14, -20.84, P = 0.01) and increased number of menstrual cycles (MD 1.06, 95% CI 0.30, 1.82, P = 0.006) after 6 months compared with lifestyle ± placebo”. In the Lifestyle + metformin versus lifestyle ± placebo section of the Results: (page 567): “Lifestyle + metformin was associated with a lower BMI at study completion compared with lifestyle + placebo (n = 493, MD -0.73 kg/m2, 95% CI -1.14, -0.32, P = 0.0005) (Fig. 3).” should be corrected to “Lifestyle + metformin showed a greater, although not statistically significant, reduction in BMI over 6 months (n = 229, MD -0.42 kg/m2, 95% CI -0.85, 0.01, P = 0.06) (Fig. 3). Two studies could not provide data on mean change in BMI (Pasquali et al, 2000 and Karimzadeh and Javedani, 2010), with the study by Pasquali et al. reporting a greater reduction in BMI over 6 months with lifestyle + metformin compared to lifestyle ± placebo.” In the Discussion (page 570): “We report for the first time in a systematic review and meta-analysis in PCOS, that in nine studies with 608 participants analysed, 6 months of combined lifestyle + metformin is associated with a lower BMI and subcutaneous fat and improved menstrual cyclicity compared with lifestyle ± placebo.” Should be replaced with “We report for the first time in a systematic review and meta-analysis in PCOS, that of nine studies with 608 participants, 229 participants had data on change in BMI over 6 months intervention with lifestyle + metformin compared to lifestyle ± placebo, showing a greater but not statistically significant reduction in BMI, significantly lower subcutaneous fat and improved menstrual cyclicity with lifestyle + metformin compared with lifestyle ± placebo.” In the Discussion (page 571): “Here we advance the field demonstrating that adding metformin at a standard dose of 1.5–2 mg daily to lifestyle intervention, resulted in a 0.73 kg/m2 lower BMI after 6 months compared to lifestyle ± placebo in women with PCOS.” to be replaced with “Here we advance the field demonstrating that adding metformin at a standard dose of 1.5–2 mg daily to lifestyle intervention, resulted in improved menstrual cyclicity, lower subcutaneous fat and a 0.42 kg/m2 greater reduction in BMI compared to lifestyle ± placebo in women with PCOS. This difference in BMI reduction didn't reach statistical significance and may be of limited clinical value. However the results were noted over only six months of intervention, and longer term, larger scale randomised clinical trials are needed to clarify the role of metformin in PCOS. The authors would like to apologise for this error.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/humupd/dmv063

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Cited by

See all 255

Metadata

Authors
Naderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J.
Venue
Human Reproduction Update
Published
2016-02-22
Volume
22
Issue
3
Pages
408-409
ISSN
  • 1355-4786 (ISSN-L)
  • 1460-2369
OpenAlex
W1836408129
Cited by
255
References
61
FWCI
7.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. https://app.cochat.ai/papers/10.1093/humupd/dmv063
The paper
Naderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2016). Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Human Reproduction Update. https://doi.org/10.1093/humupd/dmv063

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.